PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Vytorin
Schering-Plough to Merge with Merck for $41.1 Billion
Merck’s Richard T. Clark
Image via Wikipedia
Merck announced, a little over an hour ago, that it had signed an agreement with Schering-Plough’s board of directors to merge the two companies under the Merck name.
The stock and cash transaction is worth over $41 billion with Schering shareholders receiving $10.50 per share in cash and 0.5767 of a [...]
FDA Declares: Keep Taking Your Vytorin
It’s official. Vytorin (ezetimibe/simvastatin) still does what it’s supposed to do—significantly decrease LDL cholesterol.
FDA, yesterday, released its assessment of the now-notorious ENHANCE trial—which tested whether Vytorin was better than simvastatin alone in reducing arterial plaque in a group of patients with severe genetic high cholesterol. It wasn’t, and publication of the study set off a [...]
Posted in Regulatory Also tagged ENHANCE, FDA, IMPROVE-IT, Merck, Schering Plough, simvastatin Leave a comment
Merck to Axe 7,200 Positions
Not much in the way of good news at Merck this morning. The pharma giant announced that it is revising its financial guidelines through 2010, and eliminating 7,200 positions by 2011. The move is expected to save the company $3.8 billion to $4.2 billion through 2013.
The layoffs will be staggered throughout different parts of the [...]
Posted in Sales, Strategy Also tagged Gardasil, jobs, layoffs, Merck, Richard T. Clark, Zetia Leave a comment
Merck/Schering-Plough Merger Highlights (Update 1)